Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 118,886

Document Document Title
WO/2016/146583A1
The present invention relates to a compound of the general formula (II) or a salt or solvate thereof, as well as medical uses involving them, wherein A1 is selected from the group consisting of N and C-R8; A2 is selected from the group c...  
WO/2016/147144A1
A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the us...  
WO/2016/149401A2
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and composition...  
WO/2016/147185A1
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...  
WO/2016/148264A1
The problem addressed by the present invention is to provide a pharmaceutical solid preparation which comprises stabilized [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl]acetic acid monobenzene sulfonate, and to provide...  
WO/2016/148114A1
The invention of the present application can provide: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which can achieve a definitive treatment, i.e., the inhibition of cell death, rather than conventio...  
WO/2016/149092A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2016/149439A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) -(CR3R3)1-4- or (ii) -(CR3R3)x-Y-(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such c...  
WO/2016/148568A1
The invention pertains to the use of uridine and/or an equivalent thereof and n3-PUFA in the manufacture of a product for restoring or improving bladder function in a subject, in particular in a patient suffering from spinal cord injury.  
WO/2016/148260A1
Provided is a therapeutic and/or prophylactic agent or the like for early-stage Parkinson's disease which includes, as active ingredients, istradefylline (A), L-DOPA (B), and a dopamine agonist (C), and which is characterized in that the...  
WO/2016/149436A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) -(CR3R3)1-4-; (ii)-(CR3R3)x-Y-(CR3R3)y-; or (iii) -Y-(CR3R3)2-Y-; and Y, R1, R2, R3, R5, R6, R8, x, and y are defined herein. Also disclosed are methods...  
WO/2016/147108A1
The present invention relates to solid oral dosage forms of Dimethyl fumarate. More specifically, the present invention relates to delayed release compositions of Dimethyl fumarate and process for their preparation.  
WO/2016/147146A1
Citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof for use in the treatment of neurodegenerative diseases The disclosure subject matter is related to the use of citalopram or escitalopram, pharmaceutical...  
WO/2016/147011A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing ...  
WO/2016/145910A1
An application of nicotinamide adenine dinucleotide (NADH) and nicotinamide mononucleotide (NMN) in the preparation of a drug or health care product treating Parkinson's disease, β-NADH and β-NMN being prepared via enzyme catalysis.  
WO/2016/145628A1
A nutritional composition for enhancing cognitive development and learning skills comprises 3'-Siallylactose and 6'-Siallylactose in a weight ratio between 10:1 and 1:10.  
WO/2016/148232A1
The morphinan derivatives represented by general formula (I) (wherein R1 represents hydrogen, a C1-10alkyl, a cycloalkylalkyl in which the cycloalkyl moiety has 3-6 carbon atoms and the alkylene moiety has 1-5 carbon atoms, or the like; ...  
WO/2016/149169A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1and Z2are as defined in the specification, are useful in treating conditions or disorders prevented by or ...  
WO/2016/148213A1
Disclosed are: any one polypeptide selected from (a) a polypeptide which comprises the amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide which comprises an amino acid sequence produced by deleting, substituting, insertin...  
WO/2016/148308A1
The present invention provides a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment caused b...  
WO/2016/149057A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.  
WO/2016/148261A1
Provided is a therapeutic and/or prophylactic agent or the like for Lewy body diseases (such as Parkinson's disease dementia, diffuse Lewy body disease, Lewy body dementia, and Lewy body disease movement disorder) which includes istradef...  
WO/2016/145935A1
Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. ...  
WO/2016/146600A1
The present invention relates to compounds of formula I wherein Y is C-R1; R1' is hydrogen, F or Cl; R1 is F or Cl; R2 is hydrogen or lower alkyl; R3 is phenyl, pyridinyl or isothiazolyl, wherein the N atom in the pyridinyl group may be ...  
WO/2016/146026A1
The present disclosure concerns the use of gallic acid or a derivative of gallic acid. The gallic acid or the derivative of gallic acid can be an inhibitor of D-amino acid oxidase. Therefore, N-methyl-D-aspartate receptor (NMDAR) can be ...  
WO/2016/148561A1
The invention pertains to the use of uridine and/or an equivalent thereof and n3-PUFA in the manufacture of a product for restoring or improving bladder function in a subject, in particular in a patient suffering from spinal cord injury.  
WO/2016/149401A3
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and composition...  
WO/2016/146655A1
The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.  
WO/2016/145614A1
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present inven...  
WO/2016/146453A1
The present invention relates to a composition comprising palmitoylethanolamide (PEA) and a vitamin B. The present invention also relates to such a composition for use as a nutraceutical or as a medicament, for use as an analgesic pharma...  
WO/2016/146723A1
The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to tre...  
WO/2016/147659A1
Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.  
WO/2016/141756A1
A headache-relieving patch, consisting of a back lining layer, a polymer gel layer and an anti-sticking layer. The anti-sticking layer is located at an upper layer of the polymer gel layer. The back lining layer is located at a lower lay...  
WO/2016/141757A1
A nerve-soothing and eye-relaxing patch and a preparation method therefor. The patch consists of a back lining layer, a polymer gel layer and an anti-sticking layer. The gel layer is prepared from the following raw materials in percentag...  
WO/2016/144704A2
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, di...  
WO/2016/144441A1
New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention...  
WO/2016/145217A1
The present invention relates to recombinant Glut1 adeno-associated viral vector (rAAV) constructs and related methods for restoring Glut1 expression in Glut1 deficient mammals. In certain embodiments, the rAAV further comprises a chicke...  
WO/2016/142349A1
The present invention relates to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions comprising the same, to relief pain.  
WO/2016/142877A1
The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further pr...  
WO/2016/142310A1
The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also...  
WO/2016/144647A1
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and...  
WO/2016/144727A1
A combination of a non-selective, peripheral anticholinergic agent, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and method of using the same for the treatment of hypocholinergic disorders of the...  
WO/2016/145046A1
This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversi...  
WO/2016/145219A1
The present disclosure relates to methods and compositions to treat peripheral neuropathies, including demyelinating neuropathies and hereditary neuropathies, e.g., Charcot-Marie-Tooth disease. The invention provides methods and composit...  
WO/2016/144704A3
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, di...  
WO/2016/141754A1
A nerve-soothing and sleep-aiding patch, consisting of a back lining layer, a polymer gel layer and an anti-sticking layer. The anti-sticking layer is formed by a polyethylene film and is located at an upper layer of the polymer gel laye...  
WO/2016/141758A1
A patch having refreshing and cooling functions and a preparation method therefor. The patch consists of a back lining layer, a gel layer and an anti-sticking layer, which are arranged in sequence. The gel layer comprises the following c...  
WO/2016/145082A1
Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.  
WO/2016/141503A1
A stable Apremilast (represented by formula I) crystal form II free of solvates, a preparation method therefor, a pharmaceutical composition and pharmaceutical uses thereof, as well as a mixed crystal of the crystal form II and a crystal...  
WO/2016/143745A1
A composition for promoting energy metabolism, a composition for promoting sympathetic nerve activity, a composition for promoting fat burning, an antiobestic composition or a composition for elevating body temperature, each composition ...  

Matches 201 - 250 out of 118,886